Tumor necrosis factor-α is a marker of familial combined hyperlipidemia, independently of metabolic syndrome

被引:10
作者
Pauciullo, Paolo [1 ]
Gentile, Marco [1 ]
Marotta, Gennaro [1 ]
Baiano, Angela [1 ]
Ubaldi, Stefania [1 ]
Jossa, Fabrizio [1 ]
Lannuzzo, Gabriella [1 ]
Faccenda, Fulvio [1 ]
Panico, Salvatore [1 ]
Rubba, Paolo [1 ]
机构
[1] Univ Naples Federico II, Sch Med, Dept Clin & Expt Med, I-80131 Naples, Italy
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2008年 / 57卷 / 04期
关键词
D O I
10.1016/j.metabol.2007.11.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is unclear whether an association between familial combined hyperlipidemia (FCHL) and inflammatory markers exists, independently of age, sex, body weight, insulin resistance, and metabolic syndrome. Serum concentrations of soluble vascular cell adhesion molecule-1 (sVCAM-1), monocyte chemoattractant protein 1, interleukin 6, tumor necrosis factor-alpha (TNF-alpha), and high-sensitive C-reactive protein were determined in 135 probands with FCHL and in 146 normolipidernic, normotensive, normoglycemic healthy subjects. Insulin resistance was evaluated using homeostasis model assessment (HOMA). All inflammatory parameters, except interleukin 6, were significantly higher in FCHL according to medians or mean comparisons. After adjustment for age, sex, body mass index, and HOMA, only TNF-alpha remained an independent predictor of FCHL status by binary logistic regression (odds ratio [OR], 1.19; 95% confidence interval [CI], 1.07-1.31; P = .001). In particular, elevated levels of TNF-alpha (above the 90th and 95th percentiles of the value observed in the control group, 9.6 and 9.8 pg/mL, respectively) were independent predictors of FCHL status: for TNF-alpha above the 90th percentile, OR was 7.91 (95% CI, 3.27-19.13; P < .001), and for TNF-alpha above 95th percentile, OR was 13.08 (95% CI, 4.60-37.15; P <.0001). The independent role of TNF-alpha as predictor of FCHL status was confirmed after adjustment for components of the metabolic syndrome (P = .007 and P = .003, for TNF-alpha values above 90th and 95th percentiles, respectively). In conclusion, among the inflammatory markers most commonly measured, only TNF-alpha was associated with FCHL independently of age, sex, body mass index, and HOMA. The association of TNF-alpha with FCHL was also independent of the metabolic syndrome. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:563 / 568
页数:6
相关论文
共 30 条
[1]   Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death) [J].
Beckman, JA ;
Preis, O ;
Ridker, PM ;
Gerhard-Herman, M .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (10) :1374-1378
[2]  
Bredie SJH, 1997, ARTERIOSCL THROM VAS, V17, P1465
[3]   Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk [J].
Carr, MC ;
Brunzell, JD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) :2601-2607
[4]   Tumor necrosis factor alpha (TNFα) and its soluble receptor p75 (sTNF-R p75) in familial combined hyperlipidemia (FCHL) [J].
Cavallo, MG ;
Montali, A ;
Monetini, L ;
Valente, L ;
Mariani, P ;
Bifolco, M ;
Sirinian, MI ;
Antonini, TM ;
Fioretti, F ;
Campagna, F ;
Verna, R ;
Arca, M .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2005, 15 (04) :262-269
[5]   Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome - A summary of the evidence [J].
Ford, ES .
DIABETES CARE, 2005, 28 (07) :1769-1778
[6]  
Gaddi A, 1999, NUTR METAB CARDIOVAS, V9, P304
[7]   FAMILIAL LIPOPROTEIN DISORDERS IN PATIENTS WITH PREMATURE CORONARY-ARTERY DISEASE [J].
GENEST, JJ ;
MARTINMUNLEY, SS ;
MCNAMARA, JR ;
ORDOVAS, JM ;
JENNER, J ;
MYERS, RH ;
SILBERMAN, SR ;
WILSON, PWF ;
SALEM, DN ;
SCHAEFER, EJ .
CIRCULATION, 1992, 85 (06) :2025-2033
[8]   Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [J].
Grundy, SM ;
Cleeman, JI ;
Daniels, SR ;
Donato, KA ;
Eckel, RH ;
Franklin, BA ;
Gordon, DJ ;
Krauss, RM ;
Savage, PJ ;
Smith, SC ;
Spertus, JA ;
Costa, F .
CIRCULATION, 2005, 112 (17) :2735-2752
[9]   Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters [J].
Kim, C-S ;
Park, H-S ;
Kawada, T. ;
Kim, J-H ;
Lim, D. ;
Hubbard, N. E. ;
Kwon, B-S ;
Erickson, K. L. ;
Yu, R. .
INTERNATIONAL JOURNAL OF OBESITY, 2006, 30 (09) :1347-1355
[10]   Inflammatory markers and the metabolic syndrome - Insights from therapeutic interventions [J].
Koh, KK ;
Han, SH ;
Quon, MJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (11) :1978-1985